|
Name: Methaqualone
Type: Sedative-hypnotic
AKA: Quaalude, Parest, Somnafac, Opitimil, Mandrax
|
|
II. Natural Derivative
Synthetic substance, no natural derivative
 |
|
III. Chemical Profile (IUPAC name)
|
|
IV. History
Methaqualone, a sedative and hypnotic, was first synthesized in the 1950s. It was widely used as a sleep aid and anti-anxiety medication before its abuse potential led to significant regulatory controls and its decline in use.
|
|
V. Legal Information
Methaqualone, a sedative and hypnotic, is classified as a Schedule I controlled substance in the US due to its high potential for abuse and addiction. Globally, it is similarly controlled to prevent misuse and manage health risks.
US Federal Schedule - I
Schedule I drugs, substances, or chemicals are defined as drugs with no currently accepted medical use and a high potential for abuse. Some examples of Schedule I drugs are: heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), 3,4-methylenedioxymethamphetamine (ecstasy), methaqualone, and peyote.
Key US Federal Policies:
Controlled Substances Act. Public Law: Public Law 91-513 (text can be found on GovInfo) (https://www.dea.gov/drug-information/csa). Date enacted: October 27, 1970.
|
|
VI. Physical Effects
Methaqualone, a sedative-hypnotic, was used for its sedative effects. As a downer, it induces significant relaxation and drowsiness. Short-term effects included improved sleep and reduced anxiety, while long-term use led to dependence and cognitive impairment. Overdose risks involve severe sedation and respiratory depression. Safe dosing was carefully monitored. Recent findings highlight its historical use and risks of misuse.  |
|
VII. Psychological Effects
Methaqualone, a sedative-hypnotic, affects GABA-A receptors to provide sedation and mood alteration. Immediate effects include relaxation and cognitive impairment, with long-term use potentially leading to dependence and cognitive decline. Research explores its historical use and psychological impacts.
 |
|
VIII. Culture
Methaqualone is a sedative and hypnotic, classifying it as a downer. Short-term use induces sedation and sleep, while long-term use can lead to dependence, tolerance, and cognitive impairment. Overdose risks include severe sedation, respiratory depression, and potentially fatal outcomes. Safe dosages are typically prescribed by medical professionals, usually not exceeding 300 mg per day. Recent research highlights its effectiveness in inducing sleep but warns of high dependence and overdose risks. Physical effects include drowsiness, impaired coordination, and potential respiratory depression.
 |